Nantes, France, Naobios, a CDMO (Contract Development and Manufacturing Organization) providing bioprocess development and GMP production of clinical batches of viral vaccines BSL2/BSL3, oncolytic viruses and viral vectors, today announces the next phase in its partnership with FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases. Naobios will initiate the GMP manufacturing of the clinical batches of FluGen’s M2SR influenza vaccine-candidate, in preparation for their upcoming clinical trials – commencing in 2022 in the United States. Since 2019, Naobios and FluGen have collaborated on the process development of a scalable platform for FluGen’s M2SR vaccine. The company’s
The post Naobios manufactures FluGen Inc’s M2SR influenza vaccine candidate for upcoming clinical trials appeared first on Pharma Mirror Magazine.
